Please login to the form below

Not currently logged in
Email:
Password:

umeclidinium

This page shows the latest umeclidinium news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

triple – based on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate – in the US and Europe last year. ... pitted it against GSK’s two-drug LAMA/LABA Anoro (umeclidinium/vilanterol).

Latest news

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    Bevespi demonstrated non-inferiority to GSK’s Anoro (umeclidinium/vilanterol) on peak forced expiratory volume in one second (FEV1) but did not demonstrate superiority on peak FEV1 or non-inferiority on ... GSK’s Trelegy (umeclidinium/vilanterol/

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    The new US label means Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can be used in a broader population of chronic obstructive pulmonary disease (COPD) patients with difficulty breathing or who see ... GSK claims Trelegy has made the

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year.

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    Nucala itself saw sales more than double to £91m, but the approval of new triple therapy Trelegy (fluticasone furoate/umeclidinium/vilanterol) - billed as another key growth driver - came too late in

More from news
Approximately 9 fully matching, plus 51 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics